Form 4: TransMedics Group CEO Waleed Hassanein Executes Option and Sells Shares Under 10b5-1 Plan

TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 14, 2024, Waleed H. Hassanein, the President and CEO of TransMedics Group, Inc., executed a stock option to acquire 8,625 shares of common stock at a price of $13.28 per share.
• Simultaneously, Hassanein sold a total of 8,625 shares of common stock in multiple transactions at weighted average prices ranging from $140.42 to $144.52.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
• Following these transactions, Hassanein directly owns 61,643 shares of TransMedics Group, Inc. common stock and indirectly owns 469,359 shares through the Waleed H. Hassanein Revocable Trust.
• Hassanein also holds 130,750 derivative securities in the form of stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-existing plan. There's no indication of unusual activity or cause for alarm, but also no specific positive catalyst.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Industry Context

This filing is a routine disclosure of insider transactions. Monitoring such filings provides insights into management's perspective on the company's valuation and future prospects. It is common for executives to utilize 10b5-1 plans to diversify their holdings and manage personal finances.

Comparison to Industry Standards

• Executive compensation packages often include stock options and equity grants to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a common tool used by corporate insiders to sell shares while avoiding accusations of insider trading.
• The volume of shares sold is relatively small compared to the total outstanding shares of TransMedics Group, Inc.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates